Last reviewed · How we verify

Ketamine , Lidocaine , Dexmedetomidine

University of Saskatchewan · Phase 3 active Small molecule

Ketamine , Lidocaine , Dexmedetomidine is a Anesthetic combination / Sedative-analgesic combination Small molecule drug developed by University of Saskatchewan. It is currently in Phase 3 development for Anesthesia and analgesia (Phase 3 investigational combination). Also known as: Opioid-free pre-intubation medications.

This is a fixed-dose combination of three agents that work synergistically: ketamine blocks NMDA receptors for anesthesia/analgesia, lidocaine blocks sodium channels for local anesthesia, and dexmedetomidine activates alpha-2 adrenergic receptors for sedation and analgesia.

This is a fixed-dose combination of three agents that work synergistically: ketamine blocks NMDA receptors for anesthesia/analgesia, lidocaine blocks sodium channels for local anesthesia, and dexmedetomidine activates alpha-2 adrenergic receptors for sedation and analgesia. Used for Anesthesia and analgesia (Phase 3 investigational combination).

At a glance

Generic nameKetamine , Lidocaine , Dexmedetomidine
Also known asOpioid-free pre-intubation medications
SponsorUniversity of Saskatchewan
Drug classAnesthetic combination / Sedative-analgesic combination
TargetNMDA receptor (ketamine), voltage-gated sodium channels (lidocaine), alpha-2 adrenergic receptors (dexmedetomidine)
ModalitySmall molecule
Therapeutic areaAnesthesiology / Pain Management
PhasePhase 3

Mechanism of action

Ketamine provides dissociative anesthesia and analgesia through non-competitive NMDA receptor antagonism. Lidocaine provides local anesthetic effects via sodium channel blockade. Dexmedetomidine enhances sedation and analgesia through selective alpha-2 adrenergic receptor agonism, reducing the required doses of other agents while providing sympathomimetic stability. The combination is designed to provide balanced anesthesia with reduced individual drug requirements.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ketamine , Lidocaine , Dexmedetomidine

What is Ketamine , Lidocaine , Dexmedetomidine?

Ketamine , Lidocaine , Dexmedetomidine is a Anesthetic combination / Sedative-analgesic combination drug developed by University of Saskatchewan, indicated for Anesthesia and analgesia (Phase 3 investigational combination).

How does Ketamine , Lidocaine , Dexmedetomidine work?

This is a fixed-dose combination of three agents that work synergistically: ketamine blocks NMDA receptors for anesthesia/analgesia, lidocaine blocks sodium channels for local anesthesia, and dexmedetomidine activates alpha-2 adrenergic receptors for sedation and analgesia.

What is Ketamine , Lidocaine , Dexmedetomidine used for?

Ketamine , Lidocaine , Dexmedetomidine is indicated for Anesthesia and analgesia (Phase 3 investigational combination).

Who makes Ketamine , Lidocaine , Dexmedetomidine?

Ketamine , Lidocaine , Dexmedetomidine is developed by University of Saskatchewan (see full University of Saskatchewan pipeline at /company/university-of-saskatchewan).

Is Ketamine , Lidocaine , Dexmedetomidine also known as anything else?

Ketamine , Lidocaine , Dexmedetomidine is also known as Opioid-free pre-intubation medications.

What drug class is Ketamine , Lidocaine , Dexmedetomidine in?

Ketamine , Lidocaine , Dexmedetomidine belongs to the Anesthetic combination / Sedative-analgesic combination class. See all Anesthetic combination / Sedative-analgesic combination drugs at /class/anesthetic-combination-sedative-analgesic-combination.

What development phase is Ketamine , Lidocaine , Dexmedetomidine in?

Ketamine , Lidocaine , Dexmedetomidine is in Phase 3.

What are the side effects of Ketamine , Lidocaine , Dexmedetomidine?

Common side effects of Ketamine , Lidocaine , Dexmedetomidine include Dissociation/emergence reactions, Hypotension, Bradycardia, Respiratory depression, Dizziness.

What does Ketamine , Lidocaine , Dexmedetomidine target?

Ketamine , Lidocaine , Dexmedetomidine targets NMDA receptor (ketamine), voltage-gated sodium channels (lidocaine), alpha-2 adrenergic receptors (dexmedetomidine) and is a Anesthetic combination / Sedative-analgesic combination.

Related